Oral CHOP-like chemotherapy in 60-80 years-old patients with diffuse large B-cell lymphoma

Br J Haematol. 2019 Sep;186(6):e175-e178. doi: 10.1111/bjh.16056. Epub 2019 Jul 15.

Authors

Stephanie Guidez^{1

2}, Laurence Lacotte-Thierry^{1

2}, Cecile Tomowiak^{1

2}, Isabelle Princet³, Brigitte Dreyfus^{1

2}, Gaelle Olivier⁴, Emmanuel Fleck⁵, Anne Corby⁵, Carine Motard⁴, Jocelyn Barrier⁶, Antoine Machet^{1

2}, Katell Le Dû⁷, Celine Debiais-Delpech⁸, Michele Chabin³, Xavier Leleu^{1

2}, Joëlle Guilhot², Vincent Delwail^{1

2}

Affiliations

¹ Oncology-Hematology and Cell Therapy, CHU, Poitiers, France.
² INSERM CIC 1402, CHU, Poitiers, France.
³ Central pharmacy, CHU, Poitiers, France.
⁴ Internal Medecine, CH, Niort, France.
⁵ Oncology-Hematology, CH, La Rochelle, France.
⁶ Internal Medecine, CH, Chatellerault, France.
⁷ Hematology department, Clinique Victor Hugo, Le Mans, France.
⁸ Histopathology, CHU, Poitiers, France.

No abstract available

Keywords: DLBCL; age 60-80 years; chemotherapy; idarubicin; oral treatment.

Publication types

Clinical Trial, Phase I
Clinical Trial, Phase II
Letter
Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Disease-Free Survival
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Female
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy*
Lymphoma, Large B-Cell, Diffuse / mortality*
Male
Middle Aged
Prednisone / administration & dosage
Prednisone / adverse effects
Survival Rate
Vincristine / administration & dosage
Vincristine / adverse effects

Substances

Vincristine
Doxorubicin
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol

Associated data

ClinicalTrials.gov/NCT01958996